Literature DB >> 6375077

Specific binding of estramustine to prostatic proteins.

B Forsgren, P Björk.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6375077     DOI: 10.1016/s0090-4295(84)80095-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  7 in total

1.  The bleb formation of the extracellular pseudopodia; early evidence of microtubule depolymerization by estramustine phosphate in glioma cell; in vitro study.

Authors:  D Yoshida; M Noha; K Watanabe; T Bergenheim; R Henriksson; A Teramoto
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

2.  Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study.

Authors:  D Yoshida; S Hoshino; T Shimura; H Takahashi; A Teramoto
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

Review 3.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 4.  Estramustine in malignant glioma.

Authors:  A T Bergenheim; R Henriksson; J M Piepmeier; D Yoshida
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

5.  Targeting microtubule-associated proteins in glioblastoma: a new strategy for selective therapy.

Authors:  J M Piepmeier; P E Pedersen; D Yoshida; C Greer
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

6.  Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer.

Authors:  F Boccardo; A Decensi; D Guarneri; G Martorana; C Giberti; L Giuliani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.

Authors:  L A Speicher; V R Sheridan; A K Godwin; K D Tew
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.